PATRICIA CHANDHOK FULKERSON, M.D., PHD
Medical Practice in Cincinnati, OH

License number
Ohio 35.097303
Category
Medical Practice
Type
Pediatric Allergy/Immunology
Address
Address
3333 Burnet Ave. Ml, Cincinnati, OH 45229
Phone
(513) 636-6771
(513) 636-4615 (Fax)

Personal information

See more information about PATRICIA CHANDHOK FULKERSON at radaris.com
Name
Address
Phone
Patricia Fulkerson
2034 Woodside Ave, Springfield, OH 45503
Patricia Fulkerson
15567 Sandalhaven Dr, Cleveland, OH 44130
Patricia Fulkerson
1508 Attleboro Ave, Springfield, OH 45503
Patricia Fulkerson
15567 Sandalhaven Dr, Cleveland, OH 44130
Patricia Fulkerson
15269 Walnut Creek Dr, Strongsville, OH 44149

Professional information

See more information about PATRICIA CHANDHOK FULKERSON at trustoria.com
Patricia C Fulkerson Photo 1
Dr. Patricia C Fulkerson, Cincinnati OH - MD (Doctor of Medicine)

Dr. Patricia C Fulkerson, Cincinnati OH - MD (Doctor of Medicine)

Specialties:
Allergy & Immunology
Address:
3333 Burnet Ave, Cincinnati 45229
(513) 636-4315 (Phone), (513) 636-7905 (Fax)
Cincinnati Office
3333 Burnet Ave, Cincinnati 45229
(513) 636-4751 (Phone), (513) 636-8145 (Fax)
Languages:
English
Education:
Medical School
University of Cincinnati / Main Campus
Graduated: 2003


Patricia Chandhok Fulkerson Photo 2
Patricia Chandhok Fulkerson, Cincinnati OH

Patricia Chandhok Fulkerson, Cincinnati OH

Specialties:
Pediatrician
Address:
3333 Burnet Ave, Cincinnati, OH 45229


Patricia Fulkerson Photo 3
Cytokine Inhibition Of Eosinophils

Cytokine Inhibition Of Eosinophils

US Patent:
2004014, Jul 22, 2004
Filed:
Jan 7, 2004
Appl. No.:
10/752659
Inventors:
Marc Rothenberg - Cincinnati OH, US
Patricia Fulkerson - Cincinnati OH, US
International Classification:
A61K038/19
US Classification:
424/085100
Abstract:
A composition and method to alter eosinophil function and recruitment. An allergen-induced chemokine with inhibitory activity on eosinophils, monokine induced by interferon (MIG) and/or an IFN--inducible protein of 10 kDa (IP-10), is administered in a pharmaceutically acceptable dose and formulation. The composition is used for prophylaxis and therapy of diseases in which eosinophilia occurs and may be administered, for example, to allergic patients and asthmatic patients.


Patricia Fulkerson Photo 4
Cytokine Inhibition Of Eosinophils

Cytokine Inhibition Of Eosinophils

US Patent:
2005019, Sep 1, 2005
Filed:
Mar 28, 2005
Appl. No.:
11/091288
Inventors:
Marc Rothenberg - Cincinnati OH, US
Patricia Fulkerson - Cincinnati OH, US
International Classification:
A61K038/19
US Classification:
424085100
Abstract:
The cytokine CXCL9 (MIG) inhibited eosinophil responses by a CCR3- and Rac2-dependent mechanism.